N

National Institutes of Health | National Institutes of Health Clinical Center | Critical Care Medicine Department

Research site

(Unclaimed)

Location

2C137A MSC 1662, Bethesda, Maryland, United States of America

Site insights

Top conditions

Top treatments

Androgen

Bosentan

Leniolisib

AZD6244

ONC206

sirolimus

AJ201

cyclophosphamide

Thalidomide

STAR0602

Parent organization

This site is a part of National Institutes of Health

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 43 total trials

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent...

Enrolling

Abdominal Neoplasm

Neoplasms by Site

Drug: STAR0602

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of study drug AJ201...

Active, not recruiting

Spinal and Bulbar Muscular Atrophy

Kennedy's Disease

Drug: Placebo

Drug: AJ201

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi...

Active, not recruiting

Prader-Willi Syndrome

Drug: DCCR

Locations recently updated

Pediatric Patients Aged 1 to 6 Years With APDS

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic...

Enrolling

APDS

Drug: Leniolisib

Locations recently updated

Pediatric Patients Aged 4 to 11 Years With APDS

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic...

Active, not recruiting

APDS

Drug: Leniolisib

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establi...

Enrolling

Glioblastoma

Glial Tumor

Drug: ONC206